Research programme: antibody therapeutics - AbClon
Latest Information Update: 28 Dec 2019
At a glance
- Originator AbClon
- Class Bispecific antibodies
- Mechanism of Action Interleukin 6 modulators; Tumour necrosis factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Autoimmune-disorders in South Korea
- 28 Dec 2019 No recent reports of development identified for research development in Inflammation in South Korea
- 24 Nov 2015 Early research in Autoimmune disorders in South Korea (unspecified route)